Overview
- The Lancet-published ATTAIN-2 trial found the highest dose of orforglipron (36 mg) produced an average 9.6% bodyweight reduction over 72 weeks with significant improvements in blood sugar control.
- The randomized, double-blind, placebo-controlled study enrolled more than 1,500 adults with obesity and type 2 diabetes across 10 countries and reported mostly mild-to-moderate gastrointestinal side effects.
- Investigators noted the pill requires no refrigeration or food and water timing, and as a small-molecule formulation it could be manufactured at greater scale than injectable GLP-1 drugs.
- Eli Lilly says it plans regulatory submissions, with potential availability targeted for 2026 if authorized, and has framed the pill as a potentially lower-cost alternative to injections.
- Average weight loss with orforglipron was lower than leading injectable GLP-1 or dual agonists, while parallel trials of amylin-based and combination drugs report larger losses, including cagrilintide (~12%), CagriSema (>20%), and eloralintide (9–20% in phase 2).